Crowdfunding now underway for clinical study which aims to activate patient’s immune system with personalized therapeutic cancer vaccines
Lombard, IL — When it comes to chemotherapy, the risk of harm on a systemic level is well-known; An effective anti-cancer treatment in the very early stages of cancer, that can stimulate patients’ immune system has been highly sought-after. XEME Biopharma, Inc. is introducing an experimental, personalized therapeutic vaccine in asymptomatic, early stage chronic lymphocytic leukemia patients, for whom the only clinical option is “watchful waiting”, in other words waiting for the disease to progress before initiating standard treatments.
XEME Biopharma’s personalized vaccines are non-toxic treatments currently undergoing clinical trials. This marks the first in-human clinical trial in chronic lymphocytic leukemia for the vaccine, which is taking place at Northwestern University’s Lurie Cancer Center in Chicago.
While the trial can’t guarantee results, previous clinical trial experience at the National Institutes of Health – National Cancer Institute in related lymphoma patients demonstrated safety in 21 patients, with indications of efficacy
The current crowdfunding campaign aims to help change the way cancer treatment is carried out. More information can be found at www.indiegogo.com.
About XEME Biopharma, Inc.
XEME Biopharma, Inc., develops innovative, personalized therapeutic cancer vaccines for use in humans and animals.
Contact
Dr. Rich Robb, PhD,
XEME Biopharma, Inc.
Phone: 908-420-7624
E-mail: rrobb@xemebiopharma.com
Website: www.xemebiopharma.com
